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Abstract
Background: Colorectal cancer (CRC) is a major cause of cancer deaths worldwide. Accumulating evidence
suggests a potentially important role of colorectal infection with Fusobacterium nucleatum (F. nucleatum) in
colorectal carcinogenesis. We conducted a systematic review, including both a qualitative synthesis and a meta-
analysis, to synthesize the evidence from the epidemiological literature on the association between F. nucleatum
detection in the colon/rectum and CRC.
Methods: A systematic literature search of Ovid MEDLINE(R), Embase, Web of Science Core Collection, EBM
Reviews—Cochrane Database of Systematic Reviews, and CINAHL Plus with Full Text was conducted using earliest
inclusive dates up to 4 October 2020. Eligible studies were original, comparative observational studies that reported
results on colorectal F. nucleatum detection and CRC. Two independent reviewers extracted the relevant
information. Odds ratio (OR) estimates were pooled across studies using the random effects model. Newcastle-
Ottawa scale was used to critically appraise study quality.
Results: Twenty-four studies were included in the systematic review, of which 12 were included in the meta-
analysis. Studies investigated F. nucleatum in feces, colorectal tissue samples, or both. In most studies included in
the systematic review, the load of F. nucleatum was higher, on average, in specimens from CRC patients than in
those from CRC-free controls. Meta-analysis showed a positive association between F. nucleatum detection in
colorectal specimens and CRC (OR = 8.3; 95% confidence interval (95% CI) 5.2 to 13.0).
Conclusions: The results of this systematic review suggest that F. nucleatum in the colon/rectum is associated
with CRC.
Systematic review registration: This systematic review protocol has been registered with the International
Prospective Register of Systematic Reviews (PROSPERO) on July 10, 2018 (registration number
CRD42018095866).
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Background
Colorectal cancer (CRC) is a significant burden on global
public health: it is the fourth and third most commonly
diagnosed cancer in men and women [1], respectively,
with more than a million new cases per year worldwide
[2]. It is also the fourth leading cause of death from can-
cer in the world [1]. While some CRC cases are attrib-
uted to inheritance and inflammatory bowel disease,
about 80% of them are sporadic [3]. Thus, identification
of etiological factors is essential for efforts to reduce the
morbidity and mortality from CRC.
Over the years, epidemiological studies have identified
a number of CRC risk factors, such as diet, cigarette
smoking, obesity, physical inactivity, diabetes, and cer-
tain genetic polymorphisms [4–11]. Furthermore, the
role of some bacteria in colon carcinogenesis seems
quite plausible [12, 13]. In 2011, Sears and Pardoll sug-
gested that bacteria are the main drivers of the intestinal
mucosa immune response and subsequent changes in
the function and genetics of epithelial cells, which sup-
port oncogenic transformation [14]. These ideas have
rapidly gained credibility due to important discoveries
on the role of gut microbial dysbiosis and specifically of
the bacterium Fusobacterium nucleatum (F. nucleatum)
in colorectal carcinogenesis [15–25]. F. nucleatum is one
of the dominant species of 500 or more organisms that
coexist in the oral cavity [26] and the most prevalent
oral species in extra-oral infections [27, 28]. Two viru-
lence factors have been identified for F. nucleatum: an
adhesin FadA and a self-transporting protein Fap2 [28].
On the one hand, FadA allows F. nucleatum to invade
human epithelial cells, activate β-catenin signaling, in-
duce expression of the oncogenic gene, and promote the
growth of colorectal tumor cells [24, 25, 29–32]. On the
other hand, the protein Fap2 inhibits the activity of im-
mune cells and thus potentiates the progression of CCR
[32, 33]. This suggests that F. nucleatum may participate
in the colorectal tumor process and thus be a pro-
oncogenic bacterium. In a murine model of CRC (APC
+/−), the introduction of F. nucleatum increased tumor
multiplicity and the selective recruitment of myeloid
cells infiltrating tumors, thereby promoting tumor
progression [18]. F. nucleatum also stimulates the re-
cruitment of tumor-infiltrating immune cells, which gen-
erate an inflammatory microenvironment conducive to
the progression of colorectal neoplasia [18]. Mouse
tumors (APC +/−) exposed to F. nucleatum have a pro-
inflammatory expression, similar to that observed in hu-
man colorectal tumors positive for F. nucleatum [18].
Over the last decade, many subsequent studies have
reported an overabundance of F. nucleatum in colorectal
tissues and stools from subjects diagnosed with CRC
compared with CRC-free “controls.” The literature on
this topic has been growing rapidly but has not yet been
reviewed. We therefore conducted a systematic review
and a meta-analysis to review the available literature on
the association between F. nucleatum infection in the
colon and CRC.
Methods
This systematic review protocol has been registered with
the International Prospective Register of Systematic
Reviews (PROSPERO) on 10 July 2018 (registration
number CRD42018095866). The protocol for this
systematic review was published previously [34]. This
systematic review follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines as well as the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) guidelines (see Add-
itional file 1 for PRISMA checklist).
Search strategy
Literature search covered the following databases: all
Ovid MEDLINE(R), Embase, Web of Science Core Col-
lection, EBM Reviews—Cochrane Database of Systematic
Reviews, and CINAHL Plus with Full Text. A compre-
hensive search from each database’s earliest inclusive
dates (1946 for Ovid Medline, 1974 for Embase, 1945 for
Web of Science, and 2008 for EBM Reviews) to 31
December 2018 was first conducted. Specific details
regarding the search strategies appear in Table 1. The
electronic literature search was complemented by hand-
searching the list of references in the identified
publications.
An update of the literature search was then carried
out on 4 October 2020, in order to identify additional
human studies that were published in French and
English, since the initial search.
Inclusion and exclusion criteria
Eligible studies were original, comparative observational
studies that reported results on colorectal F. nucleatum
infection in at least two groups: individuals diagnosed
with CRC and colorectal-adenoma- and CRC-free sub-
jects (in this article, this population will be referred to as
“controls”). No demographic or geographic limitations
were applied. Only studies published in English or
French were included. Colorectal F. nucleatum had to
be investigated either in feces or in biopsies from tumors
in CRC patients and from healthy colorectal mucosa in
“controls.” Ascertainment of F. nucleatum infection had
to be based on microbiological detection and/or
quantification tests such as any polymerase chain
reaction (PCR) technique, sequencing, or microscopy
visualization (e.g., fluorescence in situ hybridization
technique (FISH)). Also, Fusobacterium had to be inves-
tigated at the species level, and the data had to be avail-
able for the particular species of F. nucleatum. Studies
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reporting data on genus or phylum levels only were thus
excluded. The data on the CRC status, the outcome of
interest, had to be based on laboratory-confirmed diag-
nosis (and thus had to be ascertained via a cancer regis-
try or medical records).
Study selection
Two independent reviewers (AIJ and CL) performed the
study selection process based on title and abstract.
Retained studies were then full-text screened by the
same reviewers independently to verify the inclusion
criteria. Any disagreement was resolved by discussion. If
consensus could not be reached, a third reviewer deter-
mined the eligibility and approved the final list of
retained studies.
Quality assessment and data extraction
We used the Newcastle-Ottawa Scale (NOS) to assess
the quality of the included observational studies. The
scale includes three domains: selection (4 items), com-
parability (1 item), and exposure (3 items). A study can
be awarded a maximum of one star for each numbered
item within the selection and exposure categories. A
maximum of two stars can be given for comparability.
Study quality was then classified as poor, fair, or good,
according to the Agency for Healthcare Research and
Quality (AHRQ) thresholds for converting NOS scores,
described as follows: (i) good quality = 3 or 4 stars in se-
lection domain AND 1 or 2 stars in comparability do-
main AND 2 or 3 stars in outcome/exposure domain;
(ii) fair quality = 2 stars in selection domain AND 1 or 2
stars in comparability domain AND 2 or 3 stars in
outcome/exposure domain; and (iii) poor quality = 0
or 1 star in selection domain OR 0 stars in compar-
ability domain OR 0 or 1 star in outcome/exposure
domain [35–38].
The data from each study were independently ex-
tracted by two independent reviewers (AIJ and CL, AIJ
and HS) and then reciprocally verified. Disagreements of
two reviewers were resolved by discussion. If consensus
could not be reached, a third reviewer was consulted.
The following information from each article was ex-
tracted: authors’ names, country, year of publication, aim
of the study, study design, study population, sample size
(number of cases and number of controls), study partici-
pants’ characteristics, identification sources, criteria of
matching (if any), inclusion and exclusion criteria (in-
cluding any restriction of last antibiotic consumption,
precursors of cancer, or inflammatory bowel disease
(IBD)), localization of the tumor (colon or rectal or colo-
rectal tumors), type of collected specimens (stools or bi-
opsies or both), exposure definition (frequency of
presence of F. nucleatum in specimens, relative abun-
dance, or relative quantification of bacteria load), the
Table 1 Initial search strategy
Database and search
dates
Search #1 Search #2 Search #3 Search #4 Search #5
All Ovid MEDLINE (R).
January 1, 1946, to
December 31, 2018
exp Colonic Polyps/ or exp
Colorectal Neoplasms/
((colon$ or colorect$ or rect$
or sigmoid) adj5 (polyp$ or
adeno$ or cancer$ or carcinoma$
or malignan$ or metastas$ or
neoplas$ or oncolog$ or tumo$)).tw.




Embase. January 1, 1974,
to December 31, 2018
exp Colon Polyp/ or exp
Colorectal Tumor/
((colon$ or colorect$ or rect$ or
sigmoid) adj5 (polyp$ or adeno$
or cancer$ or carcinoma$ or
malignan$ or metastas$ or neoplas$
or oncolog$ or tumo$)).tw.




CINAHL Plus with Full
Text. January 1, 1981,
to December 31, 2018
TX ((colon* or colorect* or
rect* or sigmoid) N5 (polyp*
or adeno* or cancer* or
carcinoma* or malignan* or
metastas* or neoplas*or
oncolog* or tumo*))
(MH “Colonic Polyps”) OR (MH
“Colorectal Neoplasms+”)




Web of Science Core
Collection. January 1,
1945, to December 31,
2018
TOPIC: (((colon* or colorect*
or rect* or sigmoid) NEAR/5
(polyp* or adeno* or cancer*
or carcinoma* or malignan*
or metastas* or neoplas* or
oncolog* or tumo*)))
TOPIC: (nucleatum) #1 AND #2
EBM Reviews—Cochrane
Database of Systematic
Reviews. January 1, 2005,
to December 31, 2018
((colon$ or colorect$ or rect$
or sigmoid) adj5 (polyp$ or
adeno$ or cancer$ or
carcinoma$ or malignan$ or
metastas$ or neoplas$ or
oncolog$ or tumo$)).tw.
nucleatum.tw. #1 AND #2
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technique used to detect and quantify the bacterium
load, and main results and the accompanying results of
statistical tests. For studies comparing more groups with
controls and CRC patients (e.g., adenoma or IBD pa-
tients), only data on CRC patients and controls was ex-
tracted. Similarly, when any included study performed a
second validation bacterial analysis on the same partici-
pants or on a subsample, only the results of the first
technique were extracted. (See supplementary material)
Statistical analysis
We used two approaches for data synthesis, a narrative
and a quantitative synthesis using a meta-analysis. The
descriptive synthesis was conducted according to the
Centre for Reviews and Dissemination and included text
and tables to summarize the findings.
To perform a meta-analysis, we included studies
reporting any measure of association between F. nuclea-
tum and CRC, or reporting proportions or numbers of
F. nucleatum-positive samples in CRC cases and con-
trols that allowed us to calculate estimates of odds ratios
along with the corresponding 95% confidence intervals
(CI). Then, a pooled OR estimate and its corresponding
95% CI were calculated. The data was pooled using a
random effects model [39]. Heterogeneity across studies
was tested using Cochran’s Q and the I2 statistic, and
potential publication bias was investigated by visual in-
spection of funnel plots and Egger’s regression asym-
metry test.
A subgroup meta-analysis using a random effects
model was subsequently performed in order to investi-
gate the change in F. nucleatum association to CRC by
population area, type of colorectal specimen, and
microbiological test, as well as to verify the effect of
including participants with history of IBD or a recent
antibiotic use in the included studies. Comprehensive




Initial search (31 December 2018) and its recent update
(4 October 2020) retrieved 987 records from databases
and 22 additional records through manual search of
relevant reviews. After removal of 397 duplicates, 612 ar-
ticles were screened based on titles and abstracts, which
resulted in 514 excluded articles. Ninety-eight full-text
publications were assessed for eligibility. Of these, 74
were excluded for not meeting inclusion criteria. Finally,
24 studies [40–63] were included in the systematic re-
view, of which 12 were included in the meta-analysis.
Figure 1 shows the study flow diagram.
Characteristics of studies included in the systematic
review
The characteristics of the 24 studies included in the sys-
tematic review are summarized in Table 2. Studies were
published between 2012 and 2020 and were mostly con-
ducted in Asia: twelve in China, one in Japan, and two
in Iran. Six studies were conducted in Europe (Germany,
Spain, Italy, Ireland, Norway, and Sweden), and three in
the Americas (two in USA and one in Brazil). Studies
were designed as “non-nested” case-control (n = 21),
cross sectional (n = 1), or nested case-control (n = 2),
with poor or fair quality assessment of 14 studies, ac-
cording to the AHRQ scale. Studies failed often in fulfill-
ing selection of controls and non-response rate items.
In seven studies, cases and controls were matched for
two to four variables, including age, gender, body mass
index, ethnicity, and the time period of sample collection
[42, 47, 50, 51, 53, 54, 57, 62]. There were 13 studies
that excluded subjects with reported antibiotic use in
the last month, or in the last 3 months or 6 months, and
11 studies that excluded patients previously diagnosed
with IBD.
The majority of studies investigated F. nucleatum in
feces only (18 studies), while three studies analyzed bi-
opsies only, and another three studies analyzed both
types of specimens. Quantitative PCR was the most used
bacteria-detection technique followed by sequencing
techniques, while only one study used FISH technique.
In most of the included studies, feces were collected
before colonoscopy or surgery, except for the study by
Yu et al. [60] where feces were collected more after col-
onoscopy than before. Tunsjo et al. [61] also reported
collecting feces either before colonoscopy or 1 week
after. In four studies, no information was provided about
the timing of specimen collection [43, 54, 57].
Comparison of Fusobacterium nucleatum load in
colorectal specimens between colorectal cancer cases and
controls
As shown in Table 3, F. nucleatum quantification (load) in
colorectal specimens was reported by 18 studies [41–50,
52, 53, 55, 56, 58, 60–62] including one study with two in-
dependent cohorts [49]. Bacteria quantification was
mostly performed in stool specimens, except for Yu et al.
[41] who quantified the bacteria in both feces and biop-
sies. Vogtmann et al. [53], Wang et al. [55], and Zhang
et al. [42] reported the relative abundance (RA) of the bac-
teria as a percentage, corresponding to the contribution of
F. nucleatum to the total bacteria present in specimens
[42, 53, 55]. Their results confirmed that F. nucleatum
does not naturally contribute to a healthy gut microbiome
(RA varied from 0.001 to 0.003% in controls). When in-
vestigated in CRC case specimens, F. nucleatum was sig-
nificantly more abundant than in controls, but still in very
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small proportions (RA varied from 0.061 to 0.17%). While
only four studies reported results of absolute quantifica-
tion of F. nucleatum, either as copy number or bacteria
counts, the majority of studies performed relative quantifi-
cation (RQ) of F. nucleatum to the total bacteria present
in specimens based on the ΔΔCq method. These RQ stud-
ies reported a significantly higher F. nucleatum load in
colorectal specimens of CRC patients compared to con-
trols, except for two studies [50, 52]. Fold change in F.
nucleatum from controls to CRC cases was estimated by
three studies with very different values: 132-fold according
to Wong et al. [56], 66-fold according to Tunsjo et al.
[61], and 5.2-fold reported by Xie et al. [58].
Comparison of frequency of presence of Fusobacterium
nucleatum in colorectal specimens between colorectal
cancer cases and controls
Rather than absolute or relative quantification of F.
nucleatum load, some studies compared the frequency
of presence of the bacteria in colorectal specimens
between controls and CRC patients, as shown in
Table 4. Some studies [40, 44, 49–51, 53, 54, 57, 60,
61, 63] reported the frequency of presence of the bac-
terium in colorectal specimens when the bacterium
was simply detected (by PCR, sequencing, or FISH
techniques), while other studies [45, 47, 58] reported
the frequency of presence of the bacterium when its
load level was above a specific cutoff value. The cut-
off values were typically set to the values that served
to achieve the highest discrimination between CRC
patients and controls in terms of Youden index.
Tunsjo et al. [61] set a cutoff value for detecting F.
nucleatum in feces, but not in biopsies. As shown in
Table 4, the cutoff value was not reported in one
study [58] and varied between the three others: 260
copies of F. nucleatum by Suehiro et al. [45] and a
2−ΔCq of 0.00026 (2−12) for both Eklof et al. [47] and
Tunsjo et al. [61].
Fig. 1 Flow diagram for selection of studies included in the systematic review and meta-analysis
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F. nucleatum was commonly detected in all specimens
across studies, except for Mira-Pascual et al. and Wu
et al., who did not detect the bacterium in controls’ bi-
opsies and controls’ feces respectively [50, 57]. The fre-
quency of specimens positive to F. nucleatum was
higher among CRC patients than controls in all the stud-
ies. The study by Yu et al. was the only one to use FISH
technique, which allowed for quantifying the bacteria
within tissues (called invasive F. nucleatum) and in the
biofilm separately. Their results showed a higher fre-
quency of presence of F. nucleatum in tissues than in
biofilm.
Association between Fusobacterium nucleatum and
colorectal cancer
To perform a meta-analysis on the association between
F. nucleatum and CRC, we pooled data from 12 studies
[40, 44, 49–51, 53, 54, 57, 59–61, 63] that operationally
defined the presence of F. nucleatum in terms of the de-
tection of the bacterium in colorectal specimens, with
no use of a cutoff value that optimizes distinction be-
tween cases and controls, as described above. As shown
in Fig. 2, the overall pooled OR and the corresponding
95% CI estimated in a random effects model show a
positive association between F. nucleatum detection in
colorectal specimens and CRC (OR = 8.3; 95% confi-
dence interval (95% CI) 5.2 to 13.0), with moderate het-
erogeneity (I2 = 26.32%, p value for heterogeneity =
0.18). Funnel plot for investigating publication bias is
presented in Fig. 3. Visual inspection of the funnel plot
does not suggest an evident publication bias, which was
also confirmed by Egger’s regression test (p = 0.053).
Adjusted pooled OR estimate could not be calculated
due to non-availability of adjusted OR estimates from
the reports of the individual studies.
Subgroup meta-analysis shows a stronger association
between F. nucleatum and CRC in Asiatic populations,
compared to European and American populations, as
well as in studies excluding subjects with reported anti-
biotic use in the last 3 months, compared with studies
that did not exclude these subjects (Fig. 4). However, the
association was not statistically significantly different by
specimen type (stools vs. biopsies), bacterial detection
technique (FISH vs. qPCR vs. sequencing), or previous
IBD diagnosis as exclusion criteria for study
participation.
Discussion
This systematic review summarizes results from 24 ob-
servational studies that compared the prevalence of the
presence of F. nucleatum and/or the mean/median of F.
nucleatum load in colorectal specimens, among cases of
CRC and controls. Studies used mainly two ways to
compare CRC patients and controls in regard to colorec-
tal infection by F. nucleatum: (1) bacterium load
expressed by RA (a percentage expressing the relative
contribution of F. nucleatum to total bacteria), absolute
quantification (bacteria count), or more often by RQ
(2−ΔCq value by qPCR technique, with ΔCq = (the aver-
age Cq value of F. nucleatum − the average Cq value of
total bacteria or reference gene)); and (2) frequency of
the presence of F. nucleatum in colorectal specimens.
It is true that RA and RQ are both relative measures
of the bacterium load, but many studies used one or the
other term to express the same thing, which can be con-
fusing. Thus, in this systematic review, we tried to differ-
entiate between the two terms, RA and RQ, and
represent results accordingly. This showed that RA was
used less commonly than RQ, even if RA also allows bet-
ter comparison between healthy and altered microbiome
composition, since dysbiosis is, by definition, the loss in
representation of different bacterial phyla within the
whole bacterial composition of the microbiome.
We also mention some issues with publishing data of
F. nucleatum RQ in individual studies. Most of the time,
RQ was extracted from papers’ supplementary tables or
graphs that were often poorly annotated. Also, even if
individual studies based their RQ on a common ΔΔCq
method, values were reported differently across studies.
Thus, we encourage researchers to standardize the way
to report RQ data.
Overall, results of absolute and relative quantification
of F. nucleatum were higher in CRC cases compared to
controls across most studies. Only three studies reported
the fold change of F. nucleatum load from controls to
CRC cases, but one was much larger than the others:
Fig. 2 Forest plot of the association between F. nucleatum in
colorectal specimens and colorectal cancer. Results of a random-
effects meta-analysis of 12 observational studies
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5.12-fold by Xie et al. [58], 66-fold by Tunsjo et al. [61],
and 132-fold by Wong et al. [56]. When comparing
these studies, Xie et al. [58] included subjects with
chronic inflamed colorectal mucosa within their control
group, while Wong et al. [56] excluded subjects with
IBD; Tunsjo et al. [61], for their part, did not report ex-
cluding IBD patients from participation. Presence of IBD
patients among controls in the study of Xie et al. [58]
could probably have blurred the difference in F. nuclea-
tum load between their CRC and controls. In this regard,
we mention a study by Strauss et al. who isolated Fuso-
bacterium spp. from 63.6% of patients with gastrointes-
tinal disease compared to 26.5% of healthy controls (P =
0.01), with F. nucleatum representing 69% of recovered
Fusobacterium spp. in their IBD patients [64].
Our meta-analysis included 12 studies based on a total
of 1098 cases and 1069 controls. Only crude pooled OR
could be calculated, and it shows an association between
the presence of F. nucleatum in feces or colorectal mu-
cosa and CRC.
All included studies reported results of F. nuclea-
tum detection in specimens collected just before col-
onoscopy or surgery. Furthermore, the estimated OR
for the association between F. nucleatum and CRC
was not adjusted for potential confounders. Thus,
causal explanation of the “positive” empirical associ-
ation (as quantified by the pooled-OR estimate) is not
warranted, in our view. However, the involvement of
F. nucleatum in early CRC carcinogenesis stages has
been suggested by other studies that identified the
bacterium in precancerous lesions. Its RA was re-
ported to be higher in adenomas than in healthy tis-
sues and lower in adenomas than in carcinomas,
reflecting a gradual enrichment of the colon with F.
nucleatum in parallel to the adenoma-carcinoma
sequence [65–67]. The level of F. nucleatum also
seems to increase with advancing stages of dysplasia
[43].
Subgroup meta-analysis suggested (even if weakly)
that the F. nucleatum–CRC association (if it does
exist) may be stronger in Asian populations than in
American or European ones. This finding seems to
be in line with the results of a recent meta-analysis
by Huang et al. [68] on the diagnostic value of fecal
F. nucleatum in screening CRC, which had a better
performance in Asians. The apparent dependence of
the association between F. nucleatum and CRC on
population area may be explained by lifestyle differ-
ences between populations and/or by diversity in
human gut microbiomes at the population level.
Nishijima et al. analyzed gut microbiomes of
Japanese individuals by comparing metagenomic data
obtained from 106 Japanese subjects with those from
11 other nations. They found that gut microbiome
of the Japanese is considerably different from those
of other populations and cannot be explained by
diet alone [69].
We also found that the estimated association between
F. nucleatum and CRC was stronger in the subgroup of
studies that excluded subjects with recent antibiotic use,
compared with the subgroup of studies that did not.
This can be explained by a possible bias due to introdu-
cing subjects with microbiomes altered by recent anti-
biotic use.
Some studies failed in reporting critical information,
such as time of specimen collection, which was not re-
ported by four studies [41, 43, 54, 57]. Also, in one study
[60], feces were collected most frequently after colonos-
copy. However, colonic microbiota has been shown to
be disturbed by the bowel cleansing protocol and takes
Fig. 3 Funnel plot of the natural logarithm-transformed odds ratio estimates, by the corresponding standard error. Circles, studies in
the meta-analysis
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about 2 weeks to recover to its original composition de-
pending on the cleansing protocol [70].
F. nucleatum is a very heterogeneous species of the
Fusobacteria phylum and has been classified into four to
five subspecies: animalis, nucleatum, polymorphum,
vincentii/fusiforme. F. nucleatum, subsp. nucleatum, is
mainly isolated in periodontal pathological sites, while F.
nucleatum subsp. vincentii/fusiforme is often isolated
from healthy sites as normal flora. F. nucleatum
subsp. animalis and polymorphum are associated with
complications of pregnancy, and F. nucleatum subsp.
animalis is associated with inflammatory bowel dis-
ease [71]. xIn our systematic review, data about
subspecies of F. nucleatum was only reported by the
study of Amitay et al. [40], in which the four subspe-
cies were identified: ssp. nucleatum, animalis, vincen-
tii, and polymorphum. In a study by Ye et al., five F.
nucleatum subspecies were identified in clinical CRC
specimens, with ssp. animalis being the most com-
mon one [72]. Komiya et al. examined whether identi-
cal strains of F. nucleatum could be isolated from
colorectal and saliva specimens from the same pa-
tient. Saliva and colorectal specimens were analyzed
from 14 CRC patients by qPCR, of which 40% exhib-
ited identical strains of F. nucleatum in their colorec-
tal and saliva specimens [73].
Fig. 4 Forest plots for subgroup meta-analysis. ATB, antibiotic; IBD, inflammatory bowel disease; OR, odds ratio
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The oral cavity can serve as a reservoir for the systemic
dissemination of pathogenic bacteria and their toxins,
leading to infections and inflammations in distant bodily
sites. Several oral species were identified in infections at
extraoral sites. Han et al. [28] suggested a spread of oral
infection due to transient bacteremia leading to bacterial
colonization in extraoral sites, systemic damage by toxins
free of oral pathogens, and systemic inflammation caused
by soluble antigens of oral pathogens. F. nucleatum is one
of the most dominant species of the oral microbiota [26].
It often aggregates with other oral bacteria and plays an
essential role in the formation of dental plaque, acting as a
bridge between early colonizing bacteria (Gram-positive
bacteria) and late colonizing bacteria (Gram-negative bac-
teria) [74]. Such a mechanism resembles the proposed
driver-passenger model in explaining how bacteria in the
intestinal microbiota could be involved in carcinogenesis.
The first step consists of colonization of the intestine by
pathogenic bacteria known as “drivers” with pro-
inflammatory and pro-carcinogenic potential (B. fragilis
and E. coli in particular). The tumor progression would
then cause a modification in the tumor microenviron-
ment, allowing colonization by opportunistic bacteria
known as “passengers” (F. nucleatum and Streptococcus
gallolyticus in particular), promoting further development
of the tumor [75, 76]. The bacterial “drivers” and “passen-
gers” would thus have distinct temporal roles in the
pathogenesis of CRC [75]. This model implies that there is
not a single bacterium that would alone be incriminated
in the occurrence and development of CRC, but rather a
bacterial community whose taxonomic composition con-
tinues to change throughout the tumorigenic process,
thereby allowing specific bacteria to play their role in
tumor transformation, according to their virulence and
other properties. Moreover, some believe that the oral
bacterium F. nucleatum plays a role in the development of
CRC within a bacterial community or biofilm, rather than
as an individual pathogen [77]. Warren et al. analyzed the
bacterial composition of 130 colorectal tumors and their
surrounding healthy tissues, and confirmed the over-
representation of Fusobacterium, but in the simultaneous
presence of two other commensal oral bacteria, Leptotri-
chia and Campylobacter, in individual tumors [22].
Conclusion
The results of this systematic review and meta-analysis
suggest that the F. nucleatum in feces or colorectal mu-
cosa is associated with CRC. Future clinical and epi-
demiological studies should address the potential role of
F. nucleatum in the etiology of CRC. Further, the bacter-
ium should be investigated in the colon at the subspecies
level to assess the oral origin of colorectal infection with
F. nucleatum.
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